Lung inflammatory and oxidative alterations after exogenous surfactant therapy fortified with budesonide in rabbit model of meconium aspiration syndrome
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
28006947
DOI
10.33549/physiolres.933529
PII: 933529
Knihovny.cz E-zdroje
- MeSH
- antiflogistika aplikace a dávkování MeSH
- budesonid aplikace a dávkování MeSH
- kombinovaná farmakoterapie MeSH
- králíci MeSH
- mediátory zánětu antagonisté a inhibitory metabolismus MeSH
- modely nemocí na zvířatech * MeSH
- oxidační stres účinky léků fyziologie MeSH
- peroxidace lipidů účinky léků fyziologie MeSH
- plicní surfaktanty aplikace a dávkování MeSH
- syndrom aspirace mekonia farmakoterapie metabolismus MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antiflogistika MeSH
- budesonid MeSH
- mediátory zánětu MeSH
- plicní surfaktanty MeSH
Meconium aspiration syndrome (MAS) triggers inflammatory and oxidative pathways which can inactivate both pulmonary surfactant and therapeutically given exogenous surfactant. Glucocorticoid budesonide added to exogenous surfactant can inhibit inflammation and thereby enhance treatment efficacy. Neonatal meconium (25 mg/ml, 4 ml/kg) was administered intratracheally (i.t.) to rabbits. When the MAS model was prepared, animals were treated with budesonide i.t. (Pulmicort, 0.25 mg/kg, M+B); with surfactant lung lavage (Curosurf®, 10 ml/kg, 5 mg phospholipids/ml, M+S) followed by undiluted Curosurf® i.t. (100 mg phospholipids/kg); with combination of budesonide and surfactant (M+S+B); or were untreated (M); or served as controls with saline i.t. instead of meconium (C). Animals were oxygen-ventilated for additional 5 h. Cell counts in the blood and bronchoalveolar lavage fluid (BAL), lung edema formation (wet/dry weight ratio), oxidative damage of lipids/ proteins and inflammatory expression profiles (IL-2, IL-6, IL-13, TNF-alpha) in the lung homogenate and plasma were determined. Combined surfactant+budesonide therapy was the most effective in reduction of neutrophil counts in BAL, oxidative damage, levels and mRNA expression of cytokines in the lung, and lung edema formation compared to untreated animals. Curosurf fortified with budesonide mitigated lung inflammation and oxidative modifications what indicate the perspectives of this treatment combination for MAS therapy.
Citace poskytuje Crossref.org
Acute lung injury - from pathophysiology to treatment